Market Size in Innovation: Theory and Evidence From the Pharmaceutical Industry

No 10038, NBER Working Papers from National Bureau of Economic Research, Inc

Abstract: This paper investigates the effect of (potential) market size on entry of new drugs and pharmaceutical innovation. Focusing on exogenous changes driven by U.S. demographic trends, we find that a 1 percent increase in the potential market size for a drug category leads to a 4 to 6 percent increase in the number of new drugs in that category. This response comes from both the entry of generic drugs and new non-generic drugs, and is generally robust to controlling for a variety of non-profit factors, pre-existing trends

JEL-codes: O31 O33 (search for similar items in EconPapers)
New Economics Papers: this item is included in nep-ent and nep-tid
Date: Written 2003-10
Note: HE IO PR
View list of references View citations in EconPapers

Downloads: (external link)
http://www.nber.org/papers/w10038.pdf (application/pdf)
Access to the full text is generally limited to series subscribers, however if the top level domain of the client browser is in a developing country or transition economy free access is provided. More information about subscriptions and free access is available at http://www.nber.org/wwphelp.html.

Related works:
Working Paper: Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry (2004)
Journal Article: Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry (2004)
This item may be available elsewhere in EconPapers: Search for items with the same title.

Ordering information: This working paper can be ordered from
http://www.nber.org/papers/w10038
The price is Paper copy available by mail.

Access Statistics for this paper

More papers in NBER Working Papers from National Bureau of Economic Research, Inc
Address: National Bureau of Economic Research, 1050 Massachusetts Avenue Cambridge, MA 02138, U.S.A.
Contact information at EDIRC.
Series data maintained by ().